Evidence map›Paper›PMID 38132286›Full record

ArticleBiology2023

Effects of Neonicotinoid Pesticide Metabolic Compounds on Medaka (

Hotaka Kai, Arisa Mita, Masahiro Yamaguchi

Open access · goldAbstract read
In one paragraph

Article in Biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Hotaka KaiDepartment of Chemistry and Biochemistry, National Institute of Technology (KOSEN), Suzuka College, Shiroko-Cho, Suzuka 510-0294, Mie, Japan.ORCID 0009-0009-5940-4599
Arisa MitaDepartment of Chemistry and Biochemistry, National Institute of Technology (KOSEN), Suzuka College, Shiroko-Cho, Suzuka 510-0294, Mie, Japan.
Masahiro YamaguchiDepartment of Chemistry and Biochemistry, National Institute of Technology (KOSEN), Suzuka College, Shiroko-Cho, Suzuka 510-0294, Mie, Japan.ORCID 0000-0001-5094-506X
National Institute of Technology, Kagoshima College · JP

Funding

JSPS Grant-in-Aid for Scientific Research JP18K05930
6 · The paper itself

Abstract

Neonicotinoids, including imidacloprid, are pesticides that resemble nicotine and undergo slight chemical alterations through metabolic changes in the environment. However, the effects of these metabolites on organisms remain unknown. In this study, we assessed the developmental processes of medaka embryos exposed to neonicotinoid metabolites. The target compounds were imidacloprid metabolites: 2-chloro-5-pyridine carbaldehyde (CPC) and 6-chloronicotinic acid (6-CNA). Medaka embryos within 6 h of fertilization were exposed to the compounds, and their developmental processes were observed under a stereomicroscope. Medaka embryos exposed to 5 mg/L CPC showed no abnormalities compared to the controls. Contrastingly, medaka embryos exposed to 10, 15, and 20 mg/L CPC showed abnormalities such as thrombus formation, asymmetry, disorganized development of the eyeballs, and low blood flow. This trend was more pronounced at higher CPC concentrations. On the other hand, embryos exposed to 80 and 160 mg/L 6-CNA showed no abnormalities until day 7 of exposure. However, on day 8 of exposure, sudden embryo death was observed. Both compounds may have bound to acetylcholine receptors as agonists; however, their effects were different. CPC caused abnormal development and 6-CNA caused inhibition of hatching gland development and/or synthesis of the hatching enzyme.

Indexed as

developmental anomalymedaka embryoneonicotinoid metabolitesthrombus

Identifiers

PMID38132286
PMCPMC10740882
OpenAlexW4388945262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.